The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets

Anesthesiology

Volumn 94, Issue 5, 2001, Pages 882-887

  Simoneau, Isabelle I ^a   Hamza, Maged S ^a   Mata, Heriberto P ^a   Siegel, Erin M ^c   Vanderah, Todd W ^a   Porreca, Frank ^a,b   Makriyannis, Alexandros ^d   Malan Jr , T Philip ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; MORPHINE SULFATE; NALOXONE; OPIATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; FERRET; MALE; NONHUMAN; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; VOMITING;

EID: 0035002317     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200105000-00029     Document Type: Article

References (36)

1. Campora E, Merlini L, Pace M, Bruzzone M, Luzanni M, Gottlieb A, Rosso R: The incidence of narcotic-induced emesis. J Pain Sympt Manag 1991; 6:428-30
2. Aparasu R, McCoy RA, Weber C, Mair D, Parasuraman TV: Opioid-induced emesis among hospitalized nonsurgical patients: Effect on pain and quality of life. J Pain Sympt Manag 1999; 18:280-8
3. Bhandari P, Bingham S, Andrews PL: The neuropharmacology of loperamide-induced emesis in the ferret: The role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacol 1992; 31:735-42
4. Wynn RL, Essien E, Thut PD: The effects of different antiemetic agents on morphine-induced emesis in ferrets. Eur J Pharmacol 1993; 241:47-54
5. Shoji A, Toda M, Suzuki K, Takahashi H, Takahashi K, Yoshiike Y, Ogura T, Watanuki Y, Nishiyama H, Odagiri S: Insufficient effectiveness of 5 hydroxytryptamine antagonists due to oral morphine administration in patients with cisplatin-induced emesis. J Clin Oncol 1999; 17:1926-30
6. Sussman G, Shurman J, Creed MR, Larsen LM, Ferrer-Brechner T, Noll D, Allegra J, Montgomery R, Schreck D, Grafstein E, Ramalanjaona G, Patel V, Ducharme J, Ortenwall P, Foster E, Ames M: Intravenous ondansetron for the control of opioid-induced nausea and vomiting. Clin Ther 1999; 21:1216-27
7. Stambaugh JE, Mc Adams J, Vreeland F: Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer patients with chemotherapy-induced emesis. J Clin Pharmacol 1984; 24:480-5
8. Richardson JD: Cannabinoids modulate pain by multiple mechanisms of action. J Pain 2000; 1:2-14
9. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 60:559-66
10. London SW, McCarthy LE, Borison HL: Suppression of cancer chemotherapy induced vomiting in the cat by nabilone, a synthetic cannabinoid. Proc Soc Exp Biol Med 1979; 160:437-40
11. Feigenbaum JJ, Richmond SA, Weissman Y, Mechoulam R: Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol 1989; 169:159-65
12. Ferrari F, Ottani A, Giuliani D: Cannabimimetic activity in rats and pigeons of HU210, a potent antiemetic drug. Pharmacol Biochem Behav 1999; 62:75-80
13. Lucraft HH, Palmer MK: Randomized clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 1982; 33:621-2
14. Higgins GA, Kirkpatrick GJ, Bunce KT, Jones BJ, Tyers MB: 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 1989; 97:247-55
15. Andrews PLR, Davis CL, Bingham S, Davidson HIM, Hawthorn J, Maskell L: The abdominal visceral innervation and the antiemetic reflex: pathways, pharmacology and plasticity. Can J Physiol Pharmacol 1990; 68:325-45
16. Butcher ME: Global experience with ondansetron and future potential. Oncology 1993; 50:191-7
17. Stables R, Andrews PLR, Bailey HE, Costall B, Gunning SJ, Hawthorn J, Naylor RJ, Tyers MB: Antiemetic properties of the 5-HT3 receptor antagonist GR38032F. Cancer Treat Rep 1987; 14:333-6
18. Milano S, Grelot L, Chen Z, Bianchi AL: Vagal-induced vomiting is not supressed by specific 5-HT3 receptor antagonists. J Auton Nerv Syst 1990; 31:109-18
19. Blancquaert JP, Lefebre RA, Williems JL: Emetic and antiemetic effects of opioids in the dog. Eur J Pharmacol 1986; 128:143-50
20. Barnes NM, Bunce KT, Naylor RJ, Rudd JA: The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology 1991; 30:1073-83
21. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MHN: On the receiving end: Patient perceptions of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19:203-8
22. Foss JF, Bass AS, Goldberg LI: Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J Clin Pharmacol 1993; 33:747-51
23. Costello DJ, Borison HL: Naloxone antagonizes narcotic self blockade of emesis in the cat. J Pharmacol Exp Ther 1997; 203:222-30
24. Foss JF, Yuan CS, Roizen MF, Goldberg LI: Prevention of apomorphine-or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol 1998; 42:287-91
25. Burks TF, Fox DA, Hirning LD, Shook JE, Porreca F: Regulation of gastro-intestinal function by multiple opioid receptors. Life Sci 1988; 43:2177-81
26. Naylor RJ, Rudd JA: Mechanism of chemotherapy/radiotherapy-induced emesis in animal models. Oncology 1996; 53(suppl 1):8-17
27. Galley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A: Binding of the non-classical cannabinoid CP55,940 and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 1997; 61:PL191-7
28. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A, AM630, a competitive cannabinoid receptor antagonist. Life Sci 1995; 56:1949-55
29. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM, Martin BR, Abood ME: Evaluation of the cannabinoid CB2 receptor selective antagonist, SR144528: Further evidence of cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 1999; 377:117-25
30. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1988; 83:393-411
31. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG: Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 1999; 126: 665-72
32. Rudd JA, Jordan CC, Naylor RJ: Profiles of emetic action of cisplatin in the ferret: A potential model of acute and delayed emesis. Eur J Pharmacol 1994; 262:R1-2
33. Andrews PLR, Bhandari P, Garland S, Bingham S, Davis CJ, Hawthorn J, Davidson HIM, Roylance R, Lane S: Does retching have a function? An experimental study in the ferret. Pharmacodyn Ther 1990; 9:135-52
34. Shook JE, Burks TF: Psychoactive cannabinoids reduce gastrointestinal propulsion and mobility in rodents. J Pharmacol Exp Ther 1989; 249:544-51
35. Vivian IA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH: Analgesic respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A. J Pharmacol Exp Ther 1998; 286:697-703
36. Chaperon F, Thiebot M-H: Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999; 13:243-81